<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02063529</url>
  </required_header>
  <id_info>
    <org_study_id>GIHSYSU05</org_study_id>
    <nct_id>NCT02063529</nct_id>
  </id_info>
  <brief_title>FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer</brief_title>
  <acronym>FOCULM</acronym>
  <official_title>A Phase II Study to Evaluate the Surgical Conversion Rate in Patients Receiving FOLFOXIRI +/- Cetuximab for Unresectable Wild-Type KRAS/NRAS Colorectal Cancer With Metastases Confined to the Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PURPOSE:&#xD;
&#xD;
      A primary aim of phase II FOCULM study is to explore whether cetuximab in combination with&#xD;
      FOLFOXIRI as first treatment could improve surgical conversion in patients with KRAS/NRAS&#xD;
      wild-type, unresectable liver - only metastases of colorectal cancer. The first secondary aim&#xD;
      is to evaluate the safety and tolerability of the chemotherapy of FOLFOXIRI plus Cetuximab&#xD;
      targeted therapy regimen in this patient population.&#xD;
&#xD;
      Secondary aims include determination of objective response rate, progression free survival,&#xD;
      quality of life and time to recurrence for patients undergoing complete resection and/or&#xD;
      ablation of liver.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized to two therapy groups:&#xD;
&#xD;
      Experimental arm A: Chemotherapy with FOLFOXIRI + Cetuximab Standard arm B: Chemotherapy with&#xD;
      FOLFOXIRI&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the percentage of patients who had a curative liver treatment following protocol treatment, i.e., liver metastases that can be completely resected and/or ablated with no evidence of residual malignant disease.</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reported adverse events.</measure>
    <time_frame>8 months</time_frame>
    <description>Number of patients with adverse events and severity according to NCI CTC 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>8 months</time_frame>
    <description>CR + PR rate according to RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>2 years</time_frame>
    <description>Time from date of complete resection and/or ablation of liver until first recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QLQ C30)</measure>
    <time_frame>Every 2 weeks after the first treatment until 6 months</time_frame>
    <description>scores according to EORTC QLQ-C30 scoring manual</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>A (FOLFOXIRI + Cetuximab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOXIRI + Cetuximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B (FOLFOXIRI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FOLFOXIRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOXIRI + Cetuximab</intervention_name>
    <description>Cetuximab 500mg/m² + irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles</description>
    <arm_group_label>A (FOLFOXIRI + Cetuximab)</arm_group_label>
    <other_name>Cetuximab</other_name>
    <other_name>Irinotecan</other_name>
    <other_name>Oxaliplatin</other_name>
    <other_name>Leucovorin</other_name>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOXIRI</intervention_name>
    <description>Irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles</description>
    <arm_group_label>B (FOLFOXIRI)</arm_group_label>
    <other_name>Irinotecan</other_name>
    <other_name>Oxaliplatin</other_name>
    <other_name>Leucovorin</other_name>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent obtained before any study specific procedures. Subjects must&#xD;
             be able to understand and willing to sign a written informed consent.&#xD;
&#xD;
          -  Male or female subjects &gt; 18 years &lt; 65 of age&#xD;
&#xD;
          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of&#xD;
             0 or 1 and must be considered a potential candidate for a major hepatic surgical&#xD;
             procedure.&#xD;
&#xD;
          -  Histological or cytological documentation of adenocarcinoma of the colon or rectum.&#xD;
             All other histological types are excluded.&#xD;
&#xD;
          -  There must be documentation by PET/CT scan, CT scan, MRI, or intraoperative palpation&#xD;
             (at the time of resection of the primary colorectal tumor, if applicable) that the&#xD;
             patient has evidence of metastases confined to the Liver (Histologic confirmation of&#xD;
             hepatic metastasis is not required.). The liver metastases must have been determined&#xD;
             by a hepatic surgeon approved to participate in the study to be unresectable based on&#xD;
             at least one of the following criteria: All of the liver metastases can not be&#xD;
             resected (and/or ablated) with negative margins, i.e., lesion(s) located in an area&#xD;
             that would result in the resection of all of the hepatic veins or the main portal vein&#xD;
             or the right and left hepatic arteries or the common bile duct; Complete resection&#xD;
             and/or ablation would require greater than 60% of the liver parenchyma to be removed.&#xD;
&#xD;
          -  Patients are eligible with any of the following: primary tumor and regional nodes&#xD;
             resected with clear surgical margins and no evidence of extra-hepatic disease or;&#xD;
             unresected primary tumor with plans to resect the primary tumor prior to study entry&#xD;
             or; unresected primary tumor with plans to resect the primary tumor and the liver&#xD;
             metastases in a single surgical procedure performed within 8 weeks after the last&#xD;
             preoperative dose of chemotherapy/cetuximab or; unresected primary with plans to&#xD;
             resect the primary tumor and the liver metastases in staged procedures performed&#xD;
             within 8 weeks after the last preoperative dose of chemotherapy/cetuximab.&#xD;
&#xD;
          -  The colorectal primary tumor or metastatic tumor must be determined to be KRAS and&#xD;
             NRAS wild-type.&#xD;
&#xD;
          -  At least one measurable lesion in liver metastases according to according to Response&#xD;
             Evaluation Criteria in Solid Tumors (RECIST) criteria measured within 4 weeks prior to&#xD;
             registration.&#xD;
&#xD;
          -  No previous any systemic anticancer therapy including cytotoxic therapy, signal&#xD;
             transduction inhibitors, immunotherapy and hormonal therapy for metastatic disease for&#xD;
             metastatic disease (adjuvant chemotherapy for non-metastatic disease is allowed if&#xD;
             terminated more than 6 months ago).&#xD;
&#xD;
          -  Adequate bone marrow, hepatic and renal function as assessed by the following&#xD;
             laboratory requirements conducted within 7 days of starting study treatment:&#xD;
&#xD;
          -  Leukocytes ≥ 3.0 x109/ L, absolute neutrophil count (ANC) ≥ 1.5 x109/ L, platelet&#xD;
             count ≥ 100 x109/ L, hemoglobin (Hb) ≥ 9g/ dL.&#xD;
&#xD;
          -  Total bilirubin ≤1.5 x the upper limit of normal (ULN).&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.&#xD;
&#xD;
          -  Alkaline phosphatase limit ≤ 5x ULN.&#xD;
&#xD;
          -  Amylase and lipase ≤ 1.5 x the ULN.&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x the ULN.&#xD;
&#xD;
          -  Calculated creatinine clearance or 24 hour creatinine clearance ≥ 50 mL/ min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any evidence of extra-hepatic metastases, lymph node (including portal lymph nodes)&#xD;
             metastases and primary tumor recurrence.&#xD;
&#xD;
          -  Previous hepatic resection and/or ablation, hepatic arterial infusion therapy,&#xD;
             radiation therapy to the liver (Patients who have only had an excisional biopsy are&#xD;
             eligible).&#xD;
&#xD;
          -  Previous or concurrent cancer that is distinct in primary site or histology from&#xD;
             colorectal cancer within 5 years prior to randomization.&#xD;
&#xD;
          -  Extended field radiotherapy within 4 weeks or limited field radiotherapy within 2&#xD;
             weeks prior to randomization. Subjects must have recovered from all therapy-related&#xD;
             toxicities.&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks&#xD;
             before start of study medication.&#xD;
&#xD;
          -  Uncontrolled hypertension. (systolic blood pressure &gt; 150 mmHg or diastolic pressure &gt;&#xD;
             90 mmHg despite optimal medical management).&#xD;
&#xD;
          -  Significant cardiovascular disease including unstable angina or myocardial infarction&#xD;
             within 6 months before initiating study treatment or a history of ventricular&#xD;
             arrhythmia&#xD;
&#xD;
          -  Arterial or venous thrombotic or embolic events such as cerebrovascular accident&#xD;
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism&#xD;
             within the 6 months before start of study medication.&#xD;
&#xD;
          -  Any evidence of active infection.&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Active hepatitis B or C, or chronic hepatitis B or C requiring treatment with&#xD;
             antiviral therapy.&#xD;
&#xD;
          -  History of bleeding diathesis or coagulopathy.&#xD;
&#xD;
          -  Uncontrolled hypertension. (systolic blood pressure ﹥150 mmHg or diastolic pressure ﹥&#xD;
             90 mmHg despite optimal medical management).&#xD;
&#xD;
          -  History of interstitial pneumonitis or pulmonary fibrosis&#xD;
&#xD;
          -  Pregnancy or lactation at the time of study entry.&#xD;
&#xD;
          -  Any history of or currently known brain metastases.&#xD;
&#xD;
          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency&#xD;
&#xD;
          -  Any illness or medical conditions that are unstable or could jeopardize the safety of&#xD;
             the subjects and his/her compliance in the study.&#xD;
&#xD;
          -  Unresolved toxicity higher than CTCAE v. 4.0 Grade 1 attributed to any prior&#xD;
             therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity ﹥ Grade 2.&#xD;
&#xD;
          -  Active inflammatory bowel disease or other bowel disease causing chronic diarrhea&#xD;
&#xD;
          -  Subjects with known allergy to the study drugs or to any of its excipients.&#xD;
&#xD;
          -  Current or recent (within 4 weeks prior to starting study treatment) treatment of&#xD;
             another investigational drug or participation in another investigational study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanhong Deng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gastrointestinal Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 8, 2014</study_first_submitted>
  <study_first_submitted_qc>February 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2014</study_first_posted>
  <last_update_submitted>March 28, 2020</last_update_submitted>
  <last_update_submitted_qc>March 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yanhong Deng</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>Metastatic colorectal cancer</keyword>
  <keyword>Liver metastases</keyword>
  <keyword>Liver resection</keyword>
  <keyword>Liver ablation</keyword>
  <keyword>Conversion therapy</keyword>
  <keyword>FOLFOXIRI</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>Leucovorin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

